Biogen pays Ionis $75 mln to develop muscle drug after trial success

Aug 1 Biogen Inc said it would exercise
an option to develop and commercialize an experimental genetic
muscle-disorder drug after an interim analysis of late-stage
data showed patients experienced a statistically significant
improvement in symptoms.

The drug, nusinersen, was being developed by Biogen in
collaboration with Ionis Pharmaceuticals Inc, and the
U.S. drugmaker on Monday said it had paid Ionis a $75 million
license fee.

The drug is being tested to treat spinal muscular atrophy
(SMA), a genetic disease affecting the part of the nervous
system that controls voluntary muscle movement.

In the interim analysis, nusinersen met the main goal in the
study in infants with a form of SMA, and was found to have an
acceptable safety profile.

Based on this data, the trial will be stopped, and all the
patients will now receive the drug in a follow-on study, the
companies said.

(Reporting by Natalie Grover in Bengaluru; Editing by Shounak
Dasgupta)

Source: Reuters

News

BRIEF-Moody's says Euro Area's economic recovery supports stable 2018 outlook

January 15, 2018 mmayha 0

Jan 15 (Reuters) – Moody‘s: * MOODY‘S SAYS EURO AREA‘S ECONOMIC RECOVERY SUPPORTS STABLE 2018 OUTLOOK, DESPITE PATCHY STRUCTURAL REFORM PROGRESS‍​ * MOODY‘S SAYS FORECASTS THAT EURO AREA GROWTH WILL AVERAGE 2.0 PERCENT IN 2018, […]

News

RPT-Germany to include yuan in FX reserves – c.banker

January 15, 2018 mmayha 0

(Repeats to more subscribers) HONG KONG, Jan 15 (Reuters) – Germany’s central bank has decided to include China’s currency, the yuan, in its foreign exchange reserves, Bundesbank board member Andreas Dombret said in Hong Kong […]

News

Singapore files more charges against Shell oil theft suspects

January 15, 2018 mmayha 0

SINGAPORE (Reuters) – A Singapore court on Monday filed additional charges against nine men accused in a large-scale oil theft at Shell’s biggest refinery, the latest development in an extensive investigation in the city-state. The […]

Be the first to comment

Leave a Reply